Evidence map›Paper›PMID 39229916›Full record

ArticleRenal failure2024

Early goal-directed renal replacement therapy in severe pneumonia associated acute kidney injury.

Abuduxiukuer Yusufu, Yeqing Xie, Yanting Shi, Wuhua Jiang, Jiachang Hu, Wenlv Lv, Xiaoqiang Ding, Jie Teng, Bo Shen, Jing Bi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abuduxiukuer YusufuDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Yeqing XieDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Yanting ShiDepartment of Nephrology, Xiamen Branch, Zhongshan Hospital, Fudan University, Nephrology Clinical Quality Control Center of Xiamen, Xiamen, Fujian, China.
Wuhua JiangDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Jiachang HuDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Wenlv LvDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Xiaoqiang DingDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Jie TengDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Bo ShenDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Jing BiDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianzhou ZouDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
Jiarui XuDepartment of Nephrology, Zhongshan Hospital, Fudan University, Shanghai Medical Center of Kidney, Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSevere pneumonia is a crucial issue in the development of acute kidney injury (AKI). This study evaluated the efficacy of early goal-directed renal replacement therapy (GDRRT) for the treatment of severe pneumonia-associated AKI.

methodsIn this real-world retrospective cohort study, we recruited 180 patients with severe pneumonia who were hospitalized and received GDRRT in a third-class general hospital in East China between January 1, 2017, and December 31, 2021. Clinical data on baseline characteristics, biochemical indicators, and renal replacement therapy were collected. Patients were divided into Early and Late RRT groups according to fluid status, inflammation progression, and pulmonary radiology. We investigated in-hospital all-cause mortality (primary endpoint) and renal recovery (secondary endpoint) between the two groups.

resultsAmong the 154 recruited patients, 80 and 74 were in the early and late RRT groups, respectively. There were no significant differences in the demographic characteristics between the two groups. The duration of admission to RRT initiation was significantly shorter in Early RRT group [2.5(1.0, 8.7) d vs. 5.0(1.5,13.5) d,

conclusionThis study clarified that early GDRRT for the treatment of severe pneumonia-associated AKI based on fluid status and inflammation progression, was associated with reduced hospital mortality and better recovery of renal function. Our preliminary study suggests that early initiation of RRT may be an effective approach for severe pneumonia-associated AKI.

Indexed as

Acute Kidney InjuryHospital MortalityPneumoniaRenal Replacement TherapyAgedChinaFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTime-to-TreatmentTreatment OutcomeAcute kidney injuryprognosisrenal replacement therapy (RRT)severe pneumonia

Identifiers

PMID39229916
PMCPMC11376310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.